142 related articles for article (PubMed ID: 37245521)
1. CPX-351 for higher risk myelodysplastic syndrome: cytarabine and daunorubicin in disguise?
Muus P; de Witte T
Lancet Haematol; 2023 Jul; 10(7):e481-e482. PubMed ID: 37245521
[No Abstract] [Full Text] [Related]
2. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Kim M; Williams S
Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
[TBL] [Abstract][Full Text] [Related]
3. Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alotaibi S; Niederwieser D; Ahmed SO; Sanz J; Mohty M; Aljurf M
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):575-580. PubMed ID: 35418351
[TBL] [Abstract][Full Text] [Related]
4. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
[TBL] [Abstract][Full Text] [Related]
5. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
Kolitz JE; Strickland SA; Cortes JE; Hogge D; Lancet JE; Goldberg SL; Villa KF; Ryan RJ; Chiarella M; Louie AC; Ritchie EK; Stuart RK
Leuk Lymphoma; 2020 Mar; 61(3):631-640. PubMed ID: 31760835
[TBL] [Abstract][Full Text] [Related]
6. Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients.
Stoll JR; Battle L; Moy A; Dusza SW; Park JH; Tallman MS; Taylor J; Markova A
J Am Acad Dermatol; 2022 Jan; 86(1):232-234. PubMed ID: 33539850
[TBL] [Abstract][Full Text] [Related]
7. Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes.
Triesel K; Chiang T; Seabury R; Miller C
J Oncol Pharm Pract; 2021 Sep; 27(6):1539-1541. PubMed ID: 33307969
[TBL] [Abstract][Full Text] [Related]
8. Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Keating MJ; Estey E; Kantarjian H; Plunkett W; O'Brien S; Koller C; Beran M; Freireich EJ
Leukemia; 1992; 6 Suppl 2():78-80. PubMed ID: 1578950
[No Abstract] [Full Text] [Related]
9. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Taub JW; Berman JN; Hitzler JK; Sorrell AD; Lacayo NJ; Mast K; Head D; Raimondi S; Hirsch B; Ge Y; Gerbing RB; Wang YC; Alonzo TA; Campana D; Coustan-Smith E; Mathew P; Gamis AS
Blood; 2017 Jun; 129(25):3304-3313. PubMed ID: 28389462
[TBL] [Abstract][Full Text] [Related]
10. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
11. Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review.
Howell G; Oliai C; Schiller G
Anticancer Res; 2018 Dec; 38(12):6927-6930. PubMed ID: 30504411
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
Lin TL; Newell LF; Stuart RK; Michaelis LC; Rubenstein E; Pentikis HS; Callahan T; Alvarez D; Liboiron BD; Mayer LD; Wang Q; Banerjee K; Louie AC
Cancer Chemother Pharmacol; 2019 Jul; 84(1):163-173. PubMed ID: 31098682
[TBL] [Abstract][Full Text] [Related]
13. Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.
Tavares M; Chacim S; Mariz JM
Ann Hematol; 2021 Mar; 100(3):837-839. PubMed ID: 33001280
[No Abstract] [Full Text] [Related]
14. Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
Klingler F; Alsdorf WH; Ghandili S; Wolschke C; Brauneck F; Bokemeyer C; Fiedler W; Modemann F; Karagiannis P
Leuk Lymphoma; 2022 Nov; 63(11):2645-2651. PubMed ID: 35787724
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.
Przespolewski A; Goldberg AD; Talati C; Fazal S; Vachhani P; Sanikommu SR; Thota S; Waksal J; Ball B; Famulare C; Stahl M; Baron J; Griffiths EA; Thompson JE; Sweet K; Wang ES
Blood; 2023 Mar; 141(12):1489-1493. PubMed ID: 36493344
[No Abstract] [Full Text] [Related]
16. CPX-351 (vyxeos) in AML.
Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N
Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736
[TBL] [Abstract][Full Text] [Related]
17. Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.
Buckley SA; Othus M; Vainstein V; Abkowitz JL; Estey EH; Walter RB
Am J Hematol; 2014 Apr; 89(4):423-8. PubMed ID: 24382796
[TBL] [Abstract][Full Text] [Related]
18. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
Maakaron JE; Mims AS
Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
[TBL] [Abstract][Full Text] [Related]
19. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
[TBL] [Abstract][Full Text] [Related]
20. Results of aggressive chemotherapy for myelodysplastic syndromes.
Dohy H; Kyo T
Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1428-34. PubMed ID: 3247817
[No Abstract] [Full Text] [Related]
[Next] [New Search]